RNAgene-Pampicin, Joint Research and Development of mRNA Therapeutics

[Asia Economy Reporter Hyungsoo Park] mRNA platform company RNAGENE has signed a joint research agreement with antibody drug development specialist PharmAbcine on the 18th to promote the development of mRNA anticancer and immunotherapy drugs.

RNAGENE is known to possess a highly stable drug delivery system that delivers mRNA into the body. Using effective substances discovered through a fully human antibody library containing over 100 billion diverse antibodies, they develop anticancer and immunotherapy drugs utilizing the mRNA platform. Using a human antibody library has the advantage of being suitable for antibody drug development due to low immunogenicity and toxicity caused by immune responses within the body.

Lee Woo-gil, CEO of RNAGENE, said, "By providing mRNA platform technology based on mRNA delivery technology and stabilization know-how, and PharmAbcine providing clinical expertise and various effective substances, the possibility of success is high," adding, "We have great expectations for this collaboration."

Yoo Jin-san, CEO of PharmAbcine, explained, "Producing antibody therapeutics requires complex process development and expensive production facilities. If we utilize the advantages of mRNA-based drug development, such as speed and efficiency applicable to various sequences, we will be able to develop many good therapeutics in a short period."

mRNA therapeutics are treatments that inject mRNA transcribed with genetic information into the body, allowing the human body to produce therapeutic substances directly. Since the manufacturing period is short and large-scale production is possible in a short time, it has the advantage of requiring less time and cost for initial development.

This content was produced with the assistance of AI translation services.